Total trials
680
Active
167
Phase 3
56
Total enrollment
955,110
Pipeline matrix
Showing 40 of 70 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| TNFa Antagonist - Infliximab | — | — | — | — | — | 1 | |
| TNFa Antagonist - Adalimumab | — | — | — | — | — | 1 | |
| Anti-IL12/23 or anti-IL23 - Ustekinumab | — | — | — | — | — | 1 | |
| Anti-IL12/23 or anti-IL23 - Risankizumab | — | — | — | — | — | 1 | |
| Anti-integrin - Vedolizumab IV | — | — | — | — | — | 1 | |
| Anti-integrin - Vedolizumab IV and SC | — | — | — | — | — | 1 | |
| 0.9% Sodium Chloride | — | — | — | — | — | 1 | |
| Lidocaine Injection 2% | — | — | — | — | — | 1 | |
| Low Dose Naltrexone | — | — | — | — | — | 1 | |
| Microcrystalline cellulose | — | — | — | — | — | 1 | |
| Normal saline | — | — | — | 6 | |||
| Tenecteplase | — | — | — | — | 4 | ||
| Aspirin | — | — | — | — | — | 2 | |
| Amiodarone | — | — | — | — | — | 2 | |
| Voltaren Topical Gel | — | — | — | — | — | 1 | |
| Ibuprofen Oral Suspension 100 mg/5mL | — | — | — | — | — | 1 | |
| ORA-Blend Oral Suspension | — | — | — | — | — | 1 | |
| VersaPro Cream Base for Compounding | — | — | — | — | — | 1 | |
| Atomoxetine Hydrochloride | — | — | — | — | — | 1 | |
| Low-molecular-weight heparin | — | — | — | — | — | 1 | |
| Vernakalant | — | — | — | — | — | 1 | |
| Morphine Sulfate | — | — | — | — | — | 1 | |
| Tenecteplase or Alteplase- depending upon availability at each treating centre | — | — | — | — | — | 1 | |
| Multi-strain probiotics | — | — | — | — | — | 1 | |
| ondansetron 8 mg | — | — | — | — | — | 1 | |
| Vedolizumab | — | — | — | — | — | 1 | |
| Ketorolac Tromethamine | — | — | — | — | 2 | ||
| Psilocybin | — | — | — | — | 3 | ||
| phage therapy | — | — | — | — | — | 2 | |
| Ondansetron | — | — | — | — | 2 | ||
| D-cycloserine | — | — | — | — | 5 | ||
| Budesonide MMX® | — | — | — | — | — | 1 | |
| Budesonide controlled ileal release (CR) | — | — | — | — | — | 1 | |
| Psilocybin high-dose | — | — | — | — | — | 1 | |
| Psilocybin low-dose | — | — | — | — | — | 1 | |
| Risperidone 1 MG | — | — | — | — | — | 1 | |
| Five phage anti-Staphylococcus aureus bacteriophage cocktail | — | — | — | — | — | 1 | |
| Maraviroc | — | — | — | — | — | 1 | |
| subcutaneous Teriparatide | — | — | — | — | — | 1 | |
| Ivabradine 4-week course | — | — | — | — | — | 1 |
30 more active programs hidden
Next readouts
- 2025-03
- 2025-08
- 2025-11
- 2025-11-30
- 2025-12
- 2025-12-31
- 2025-12-31
- 2026-03
- 2026-06-30
- 2026-07
Top conditions
- Stroke18
- Cancer13
- Obesity13
- Atrial Fibrillation11
- Depression10
- Hypertension9
- Asthma9
- Coronary Artery Disease8
Frequently asked questions about University of Calgary
- How many clinical trials does University of Calgary have on ClinicalTrials.gov?
- University of Calgary is listed as the lead sponsor on 680 clinical trials in ClinicalTrials.gov, 167 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Calgary's trials are in Phase 3?
- 56 of University of Calgary's trials are in Phase 3, spread across 70 active drug programs.
- What therapeutic areas does University of Calgary focus on?
- University of Calgary's most-studied conditions on ClinicalTrials.gov are Stroke, Cancer, Obesity, Atrial Fibrillation, Depression.
- When are University of Calgary's next clinical trial readouts?
- University of Calgary has 10 upcoming primary-completion readouts tracked here; the soonest is “HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)”, expected around 2025-03.